GOSS Gossamer Bio Inc
Company Analysis
Latest News
🔴 Gossamer Bio is trading 5.29% down today amid a 4.24% biotech sector ETF decline
Gossamer Bio is trading 5.29% down now at $0.16 after broader biotech weakness. - The biotech sector ETF is down 4.24%, making sector pressure the clearest...
🟢 Gossamer Bio is trading 5.53% up today
Gossamer Bio is trading at $0.18, up 5.53%, with no clear company-specific catalyst identified. - No company-specific announcement dated August 31, 2026 was...
H.C. Wainwright Reaffirms 'Buy' Rating for Gossamer Bio Amid NDA Progress for Seralutinib
H.C. Wainwright reiterates a "Buy" rating and a $2.00 price target for Gossamer Bio Inc. shares. Gossamer prepares to submit a New Drug Application (NDA) for...
🟢 Gossamer Bio is trading 7.02% up in pre-market with no confirmed overnight catalyst
Gossamer Bio is trading at $0.19 (+7.02%) in pre-market, with the move appearing speculative or liquidity-driven. - No new August 27, 2026 company-specific...
Gossamer Bio's $250 Million Lifeline Comes at a Steep Price — Can an FDA Bet Justify the Dilution?
Shares slid 10.3% to $0.18 on August 26, bucking a strong biotech tape (XBI up 2.06%), as investors took a harder look at the massive dilution embedded in...
🔴 Gossamer Bio is trading 10.61% down today after investors reassessed dilution risk
Gossamer Bio is trading 10.61% down now at $0.18 as investors reassess dilution risk from its structured private placement. - Financing includes pre-funded...
🔴 Gossamer Bio is trading 9.7% down today amid dilution and financing-overhang concerns
Gossamer Bio is trading 9.7% down at $0.18 as investors appeared to reassess dilution and financing overhang from its recently announced structured private...